At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
Research and Development (R&D) Standard of Excellence
Neurological diseases are the leading cause of disability and the second-leading cause of death worldwide.1 We believe that the pathways of neurological diseases are interrelated and so are the potential approaches for treating them.
We leverage our knowledge about pathophysiological processes and disease characteristics to pioneer new potential treatments and further other areas of research and development. There’s more to come as we continue to chase the possibilities and strive to make a difference for patients everywhere.
Biogen R&D is driven by the potential to transform the lives of patients. We work in disease areas with some of the greatest unmet need. We work relentlessly knowing that bold, new possibilities await discovery. As pioneers in neuroscience, we work toward those once-in-a-lifetime moments that could become a historic point in our pursuit of innovative treatments.
Explore Career Opportunities
Do you believe that each day holds boundless potential like we do?
Because neurological diseases devastate so many people worldwide, we believe no other disease area holds as much unmet need or as much promise.
Core Growth Areas
Multiple Sclerosis and Neuroimmunology
We have a diverse portfolio of approved drugs to treat MS. We are taking a variety of approaches to further our understanding of this disease and how to treat it.
Alzheimer’s Disease and Dementia
Our diverse portfolio of investigational products includes several assets targeting early-stage Alzheimer’s disease. We hope to capitalize on advances in molecular and cellular biology and connect them with discoveries in human genetics.
Neuromuscular Disorders Including SMA and ALS
Our efforts in neuromuscular disorders are focused on two main areas: spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We have brought forward the first approved therapy for SMA, and our scientists continue to work toward new potential therapeutics for SMA patients while advancing potential therapies for ALS.
Parkinson’s Disease and Movement Disorders
We currently have a preclinical and clinical portfolio around Parkinson’s disease (PD) and other movement disorders, targeting core disease genetics and pathology.
Biogen’s ophthalmology portfolio bolsters our pipeline across complementary modalities while leveraging our extensive expertise in disorders of the central nervous system. Our leading gene therapy programs target two inherited retinal disorders: choroideremia and X-linked retinitis pigmentosa.
Neuropsychiatry is an area of significant unmet patient need that intersects with other neurological disorders in our core therapeutic areas.
Emerging Disease Areas
Leveraging our expertise in neuroimmunology, we are excited by the possibility of pioneering new scientific breakthroughs in immunology.
We have an innovative portfolio of compounds that target peripheral immune cell infiltration, brain edema, glial cell activation and cell death pathways, which have the potential to transform clinical care paradigms in acute brain injury.
Our approach to pain therapeutics includes selecting drug targets and pathways in rare genetic conditions, testing new drug candidates in patient populations with severe pain conditions, and exploring the possibility of combining multiple approaches for engaging a drug target.
With capabilities in multiple drug modalities, including small molecules, protein therapeutics, antisense oligonucleotides and gene therapy, Biogen pursues the most appropriate modality for each target.
Small molecule therapeutics are often taken orally, as a pill, and can readily distribute into cells and tissues, which differentiates them from other modalities. Medicinal chemists aim to optimize the potency of starting molecules towards the desired biological target along with physical properties to maximize the potential of the medicine to treat disease.
Therapeutic proteins, also referred to as biologics, are often as much as a thousand times the size of small-molecule drugs. Although this type of drug is much more complicated to make and characterize, using biologics allows scientists to attack serious disease in ways that might not be possible with other technologies.
Antisense oligonucleotides (ASOs) are synthetic, single-stranded nucleic acids consisting of 8 to 50 nucleotides which bind to RNA and are designed to interfere with target gene expression. ASOs utilize several distinct mechanisms to alter RNA and either restore desired protein expression or reduce and modify toxic proteins.
Gene therapies target the root causes of genetic diseases. They expand our potential to treat previously intractable diseases by capitalizing on recent advances in our understanding of human genetics.
Partner with Us
We welcome the opportunity to explore working with other innovators. If your company or institution would like to share a potential asset or platform technology for collaboration, contact us today at email@example.com.
Explore Career Opportunities
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.